Herpes virus thymidine kinases are responsible for the activation of nucleoside antiviral drugs including (E)-5-(2-bromovinyl)-2-deoxyuridine. Such viral thymidine kinases (tk), beside having a broader substrate specificity compared with host cell enzymes, also show significant variation in nucleoside phosphorylation among themselves. We have determined the crystal structure of Varicella zoster virus (VZV, human herpes virus 3) thymidine kinase complexed with (E)-5-(2-bromovinyl)-2-deoxyuridine 5-monophosphate and ADP. Differences in the conformation of a loop region (residues 55-61) and the position of two ␣-helices at the subunit interface of VZV-tk compared with the herpes simplex virus type 1 (human herpes virus 1) enzyme give rise to changes in the positioning of residues such as tyrosine 66 and glutamine 90, which hydrogen bond to the substrate in the active site. Such changes in combination with the substitution in VZV-tk of two phenylalanine residues (in place of a tyrosine and methionine), which sandwich the substrate pyrimidine ring, cause an alteration in the positioning of the base. The interaction of the (E)-5-(2-bromovinyl)-2-deoxyuridine deoxyribose ring with the protein is altered by substitution of tyrosine 21 and phenylalanine 139 (analagous to herpes simplex virus type 1 histidine 58 and tyrosine 172), which may explain some of the differences in nucleoside sugar selectivity between both enzymes. The altered active site architecture may also account for the differences in the substrate activity of ganciclovir for the two thymidine kinases. These data should be of use in the design of novel antiherpes and antitumor drugs.Varicella zoster virus (VZV 1 ; human herpes virus 3) is the causative agent for both a primary (chicken pox or Varicella) and a secondary disease (shingles or zoster), the latter results from activation of the latent virus. Whereas Varicella is generally considered to be a mild childhood disease, in adults it may be complicated by pneumonia and encephalitis and in immunocompromised patients it is associated with significant morbidity and mortality (1).The mammalian thymidine kinase is part of the pyrimidine salvage pathway and catalyzes the transfer of the ␥-phosphoryl group from ATP to thymidine to give thymidine monophosphate. Both HSV1-tk (human herpes virus 1-tk) and VZV-tk have an additional thymidylate kinase activity that converts thymidine monophosphate to thymidine diphosphate. The substrate specificity of VZV-tk is also broader than the host cell kinase with a wide range of nucleoside analogues able to be phosphorylated (2-4). Many of the drugs utilized to treat herpes virus infections are nucleoside analogues such as the pyrimidine nucleoside BVDU or the guanine nucleoside analogues, aciclovir and ganciclovir (Scheme 1), which are activated by the viral thymidine kinase (4).Thus, the broad substrate specificity of herpes virus thymidine kinases is of interest pharmaceutically, both for the action of antiviral drugs and increasingly for their potential use in enzyme ...